Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Haichang to fund development through completion of Phase IIa Proof-of-Concept Clinical Trial Clinical trials will be designed to meet both the US and China FDA requirements ROCKVILLE, Md., Feb. 08,...
-
ROCKVILLE, Md., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the...
-
ROCKVILLE, Md., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
-
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Metastatic Pancreatic Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments ...
-
ROCKVILLE, Md., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the...
-
ROCKVILLE, Md., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the...
-
ROCKVILLE, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
-
Supinoxin enhances the efficacy of immunotherapy in multiple preclinical models Supinoxin shows potent activity against patient-derived triple negative breast cancer (TNBC) tumors in preclinical...
-
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment...
-
ROCKVILLE, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), today announced that it has dosed the first patient in a Phase IIa clinical study of RX-3117 in...